| β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin G Daniele, A Tura, A Brocchi, A Saba, B Campi, V Sancho-Bornez, ... Diabetes Care 47 (7), 1131-1139, 2024 | | 2024 |
| Continuous glucose monitoring for the routine care of type 2 diabetes mellitus RA Ajjan, T Battelino, X Cos, S Del Prato, JC Philips, L Meyer, J Seufert, ... Nature Reviews Endocrinology 20 (7), 426-440, 2024 | 1 | 2024 |
| 415-P: Different Diabetic Kidney Disease (DKD) Phenotypes and Urinary Fetuin-A Levels in Subjects with Type 2 Diabetes M GAROFOLO, D LUCCHESI, M GIAMBALVO, M CAPOBIANCO, ... Diabetes 73 (Supplement_1), 2024 | | 2024 |
| Cost–utility analysis of a flash continuous glucose monitoring system in the management of people with type 2 diabetes mellitus on basal insulin therapy—An Italian healthcare … S Del Prato, F Giorgino, K Szafranski, Y Poon Diabetes, Obesity and Metabolism, 2024 | | 2024 |
| DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases Y Handelsman, JE Anderson, GL Bakris, CM Ballantyne, DL Bhatt, ... Metabolism, 155931, 2024 | 38 | 2024 |
| GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes S Ciardullo, ML Morieri, G Daniele, TV Fiorentino, T Mezza, D Tricò, ... Acta Diabetologica, 1-10, 2024 | | 2024 |
| 2024: The year to take European action on diabetes to the next level S Del Prato, B Torbeyns, C Mathieu, European Diabetes Forum Board Diabetologia, 1-4, 2024 | | 2024 |
| Indirect effects of the COVID-19 pandemic on diagnosing, monitoring, and prescribing in people with diabetes and strategies for diabetes service recovery internationally MK Rutter, MJ Carr, AK Wright, N Kanumilli, N Milne, E Jones, P Elton, ... Diabetes Research and Clinical Practice, 111693, 2024 | | 2024 |
| Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial MP Gilbert, J Skelly, AF Hernandez, JB Green, KA Krychtiuk, CB Granger, ... Diabetes, Obesity and Metabolism 26 (5), 1714-1722, 2024 | | 2024 |
| The current landscape for diabetes treatment: Preventing diabetes-associated CV risk A Dardano, C Bianchi, M Garofolo, S Del Prato Atherosclerosis, 117560, 2024 | 1 | 2024 |
| Randomized trial of a selective aldose reductase inhibitor in patients with diabetic cardiomyopathy JL Januzzi Jr, J Butler, S Del Prato, JA Ezekowitz, NE Ibrahim, CSP Lam, ... Journal of the American College of Cardiology, 2024 | 4 | 2024 |
| ALBIGLUTIDE AND ATRIAL FIBRILLATION/ATRIAL FLUTTER IN PATIENTS WITH TYPE 2 DIABETES AND ESTABLISHED CARDIOVASCULAR DISEASE-A SECONDARY ANALYSIS OF THE HARMONY OUTCOMES TRIAL KA Krychtiuk, G Marquis-Gravel, S Murphy, KE Chiswell, J Green, ... Journal of the American College of Cardiology 83 (13_Supplement), 1888-1888, 2024 | | 2024 |
| Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial HC Gerstein, R Mian, C Ramasundarahettige, KRH Branch, S Del Prato, ... Diabetes, Obesity and Metabolism 26 (4), 1216-1223, 2024 | | 2024 |
| Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk GP Fadini, E Longato, ML Morieri, S Del Prato, A Avogaro, A Solini, ... The Lancet Regional Health–Europe 38, 2024 | 2 | 2024 |
| Cardio‐renal‐metabolic disease in primary care setting M Ibrahim, EM Ba‐Essa, J Baker, A Cahn, A Ceriello, F Cosentino, ... Diabetes/metabolism research and reviews 40 (3), e3755, 2024 | 1 | 2024 |
| Fatty liver index is an independent risk factor for all-cause mortality and major cardiovascular events in type 1 diabetes: an 11-year observational study M Garofolo, D Lucchesi, M Giambalvo, M Aragona, A Bertolotto, F Campi, ... Cardiovascular Diabetology 23 (1), 85, 2024 | | 2024 |
| Abnormalities of insulin secretion and β‐cell defects in type 2 diabetes S Del Prato, C Bianchi, G Daniele Textbook of Diabetes, 225-237, 2024 | 12 | 2024 |
| Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial JL Januzzi, S Del Prato, J Rosenstock, J Butler, J Ezekowitz, NE Ibrahim, ... Cardiovascular Diabetology 23 (1), 49, 2024 | 3 | 2024 |
| Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial KA Krychtiuk, G Marquis-Gravel, S Murphy, KP Alexander, K Chiswell, ... European Heart Journal-Cardiovascular Pharmacotherapy, pvae006, 2024 | | 2024 |
| Physical Activity Levels And Cardiac Functional Capacity In Patients With Diabetic Cardiomyopathy: Baseline Analysis From The Arise-HF Trial J Butler, S Del Prato, J Ezekowitz, N Ibrahim, C Lam, T Marwick, R Perfetti, ... Journal of Cardiac Failure 30 (1), 310, 2024 | | 2024 |
